更昔洛韦治疗婴儿巨细胞病毒性肝炎的疗效观察

Survey on curative effect of infant cytomegalic viral hepatitis treated by Ganciclovir

目的观察更昔洛韦（GCV）治疗婴儿巨细胞病毒（CMV）性肝炎的临床疗效。方法对56例诊断为巨细胞病毒性肝炎患儿给予治疗，观察治疗前后临床症状改善情况、血常规变化及CMV—IgM转阴率。结果治疗2周CMV—IgM转阴率为55．3％，4周CMV—IgM转阴率为80．3％。GCV治疗后血清总胆红素（TBIL）由[（105．56±14．20）μmol／L]降至[（75．25±9．51）μmol／L]，血清谷丙转氨酶（ALT）由[（125．56±82．25）IU／L]降至[（56．40±35．50）IU／L]，碱性磷酸酶（ALP）在治疗前后无明显改变；治疗2周未观察到明显的药物不良反应。结论GCV是治疗CMV性肝炎有效药物之一。

Objective To observe on curative effect of infant cytomegalic viral hepatitis treated by Ganciclovir. Method 56 cases diagnosed as cytomegalic viral hepatitis were treated by GCV, surveyed the improving situation about clinical symptoms before and after treatment, the change of blood routine and the negative conversion rate of CMV-IGM. Result The negative conversion rate of CMV-IGM is 55.3% after two-week curing,the negative conversion rate of CMV-IGM is 80. 3% after four-week curing. Total bilirubin（TBIL） in serum dropped from [ （ 105.56± 14. 20） μmol/L] to [ （75.25 ± 9.51 ） μmol/L], and ALT in serum dropped from [ （ 125.56± 82. 25 ） IU/L] to [ （56.40 ± 35.50）IU/L ] after treated by GCV, and ALP had no obvious change before and after treatment. The treatment of two-week curing had not been observed obvious adverse reactions. Conclusion GCV is one of effective drug to treat cytomegalic viral hepatitis.